أعرض تسجيلة المادة بشكل مبسط
| dc.contributor |
Epicentre, Paris, France. |
|
| dc.creator |
Pécoul, B |
|
| dc.creator |
Varaine, F |
|
| dc.creator |
Keita, M |
|
| dc.creator |
Soga, G |
|
| dc.creator |
Djibo, A |
|
| dc.creator |
Soula, G |
|
| dc.creator |
Abdou, A |
|
| dc.creator |
Etienne, J |
|
| dc.creator |
Rey, M |
|
| dc.date |
1991-10-05 |
|
| dc.date.accessioned |
2017-01-31T07:10:13Z |
|
| dc.date.available |
2017-01-31T07:10:13Z |
|
| dc.identifier |
Long-acting chloramphenicol versus intravenous ampicillin for treatment of bacterial meningitis. 1991, 338 (8771):862-6 Lancet |
|
| dc.identifier |
0140-6736 |
|
| dc.identifier |
1681224 |
|
| dc.identifier |
http://hdl.handle.net/10144/19393 |
|
| dc.identifier |
http://fieldresearch.msf.org/msf/handle/10144/19393 |
|
| dc.identifier |
Lancet |
|
| dc.identifier.uri |
http://dspace.mediu.edu.my:8181/xmlui/handle/10144/19393 |
|
| dc.description |
In most developing countries, bacterial meningitis (BM) is associated with a high case-fatality rate. The search for a simple, convenient, and inexpensive antibiotic treatment remains a priority. In this study, a non-blinded, multicentre, randomised clinical trial of 528 cases of BM was done in two hospitals in Mali and Niger, between March, 1989, and May, 1990, to see whether a double injection of long-acting chloramphenicol (on admission to hospital and 48 h later) is as effective as a course of intravenous ampicillin (8 days, 4 times a day). The cumulative case-fatality rate on day 4 (principal end-point) among the chloramphenicol (254 patients) and ampicillin (274) groups were, respectively, 28% and 24.5% (relative risk 1.14, 95% confidence interval 0.86-1.52). No outbreak occurred during the study period. The hospital case-fatality rate was 33.1%. Main risk factors for death were associated with clinical condition on admission--ie, altered consciousness, convulsions, or dehydration. The case-fatality rates were 13% (21/161) for Neisseria meningitidis, 36.1% (48/133) for Haemophilus influenzae, and 67% (77/115) for Streptococcus pneumoniae. In a multiple logistic regression model, controlling for the differential distribution of potential risk factors (including bacterial species), there was no difference between treatment groups. Our findings suggest that long-acting chloramphenicol is a useful first-line presumptive treatment for BM in high-incidence countries. |
|
| dc.language |
en |
|
| dc.publisher |
Elsevier |
|
| dc.relation |
http://www.thelancet.com |
|
| dc.rights |
Reproduced on this site with permission of Elsevier Ltd. Please see www.thelancet.com for further relevant comment. |
|
| dc.title |
Long-acting chloramphenicol versus intravenous ampicillin for treatment of bacterial meningitis. |
|
الملفات في هذه المادة
|
لا توجد أي ملفات مرتبطة بهذه المادة.
|
هذه المادة تبدو في المجموعات التالية:
أعرض تسجيلة المادة بشكل مبسط